Filing Details
- Accession Number:
- 0001127602-22-010749
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-31 16:49:58
- Reporting Period:
- 2022-03-30
- Accepted Time:
- 2022-03-31 16:49:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 64803 | Cvs Health Corp | CVS | Retail-Drug Stores And Proprietary Stores (5912) | 050494040 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1900910 | S Prem Shah | One Cvs Drive Woonsocket RI 02895 | Evp And Co-President Of Retail | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-03-30 | 5,346 | $102.26 | 64,417 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-03-30 | 5,346 | $104.70 | 59,071 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Disposition | 2022-03-30 | 5,346 | $0.00 | 5,346 | $102.26 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-04-01 | 2022-04-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock (Pep) | 4,413 | Direct | |
| Common Stock (Restricted) | 1,925 | Direct | |
| Common Stock (Restricted) | 6,393 | Direct | |
| Common Stock (Restricted) | 1,808 | Direct | |
| Common Stock (Restricted) | 15,427 | Direct | |
| Common Stock (Restricted) | 2,884 | Direct | |
| Esop Common Stock | 4,539 | Direct | |
| Common Stock (Restricted) | 1,866 | Direct | |
| Stock Unit (Deferred) | 5,672 | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | $104.82 | 2017-04-01 | 2023-04-01 | 2,935 | 2,935 | Direct |
| Common Stock | Stock Option | $62.20 | 2019-04-01 | 2025-04-01 | 1,691 | 1,691 | Direct |
| Common Stock | Stock Option | $54.19 | 2020-04-01 | 2029-04-01 | 12,626 | 12,626 | Direct |
| Common Stock | Stock Option | $58.34 | 2021-04-01 | 2030-04-01 | 34,315 | 34,315 | Direct |
| Common Stock | Stock Option | $74.30 | 2022-04-01 | 2031-04-01 | 32,826 | 32,826 | Direct |
| Common Stock | Stock Option | $75.24 | 2021-08-31 | 2028-08-31 | 26,580 | 26,580 | Direct |
| Common Stock | Phantom Stock Credits | $1.00 | 11,259 | 11,259 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2023-04-01 | 2,935 | 2,935 | Direct |
| 2025-04-01 | 1,691 | 1,691 | Direct |
| 2029-04-01 | 12,626 | 12,626 | Direct |
| 2030-04-01 | 34,315 | 34,315 | Direct |
| 2031-04-01 | 32,826 | 32,826 | Direct |
| 2028-08-31 | 26,580 | 26,580 | Direct |
| 11,259 | 11,259 | Direct |
Footnotes
- All sales were effected pursuant to a Rule 10b5-1 plan.
- Consists of Matching RSUs awarded pursuant to Issuer's Partnership Equity Program, a sub-plan under its ICP, and dividend equivalents on the Matching RSUs. Restrictions lapse on the RSUs on 08/31/2023.
- Consists of remaining RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 ICP. Restrictions lapse in two equal installments commencing on 02/28/2022.
- Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in four equal installments commencing on 04/01/2022.
- Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions lapse on 04/01/2022.
- Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in three equal installments commencing on 04/01/2022.
- Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in two equal installments commencing on 04/01/2022.
- Consists of RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan under its 2017 ICP. Restrictions lapse in three equal installments commencing on 02/26/2022.
- Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
- Option becomes exercisable in four equal installments commencing 04/01/2016.
- Option becomes exercisable in four equal installments commencing 04/01/2017.
- Option becomes exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
- Option becomes exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised.
- Option becomes exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
- Option becomes exercisable in three equal installments commencing 04/01/2022.
- Option vests in three equal installments, on 8/31/2021, 8/31/2022 and 8/31/2023.
- Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
Billionaire Hedge Funds
